1-5 of 5
Emily Pittman
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Phase II Study of the Combination of Daratumumab, Ixazomib, Pomalidomide, and Dexamethasone in Early Relapsed/Refractory Multiple Myeloma

Anupama Kumar, Aaron S Rosenberg, Michelle Padilla, Nina Shah, Lindsey Sirianni, Lin Liu, Yuwei Cheng, Emily Pittman, Dimitrios Tzachanis, Sarah Larson, Carolyn Mulroney, Edward D. Ball, Caitlin Costello
Journal: Blood
Blood (2022) 140 (Supplement 1): 4436–4437.
https://doi.org/10.1182/blood-2022-169838
Published: 2022
Journal Articles

Rituximab and High-Dose Methylprednisolone Debulking Prior to Venetoclax for Patients with Relapsed or Refractory CLL

Michael Y. Choi, Benjamin Heyman, Minya Pu, Emily Pittman, Karen Messer, Thomas J. Kipps
Journal: Blood
Blood (2022) 140 (Supplement 1): 12410–12411.
https://doi.org/10.1182/blood-2022-170897
Published: 2022
Journal Articles

Cirmtuzumab Consolidation for Treatment of Patients with Detectable CLL on Venetoclax

Benjamin Heyman, MD, Michael Y. Choi, MD, Emanuela M. Ghia, PhD, George F. Widhopf II, PhD, Minya Pu, PhD, Emily Pittman, PhD, Karen Messer, PhD, Catriona Jamieson, MD PhD, Thomas J. Kipps, MD PhD
Journal: Blood
Blood (2020) 136 (Supplement 1): 13.
https://doi.org/10.1182/blood-2020-134711
Published: 2020
Journal Articles

Durable and Specific Inhibition of ROR1 Signaling Associates with Prolonged Progression Free Survival in Patients with Chronic Lymphocytic Leukemia Treated with Cirmtuzumab

Michael Choi, MD, George F. Widhopf II, PhD, Jian Yu, PhD, Liguang Chen, PhD, Md. Kamrul Hasan, PhD, Laura Z. Rassenti, PhD, Emily Pittman, PhD, Karen Messer, PhD, Charlene Gutierrez, BS, Reilly Lilianna Kidwell, BSc, Charles E. Prussak, PharmD, PhD, Januario E Castro, MD, Catriona Jamieson, MD PhD, Thomas J. Kipps, MD
Journal: Blood
Blood (2017) 130 (Supplement 1): 829.
https://doi.org/10.1182/blood.V130.Suppl_1.829.829
Published: 2017
Journal Articles

Immunotherapeutic Targeting of ROR1-Dependent, Non-Canonical Wnt5a-Signaling By Cirmtuzumab: A First-in-Human Phase I Trial for Patients with Intractable Chronic Lymphocytic Leukemia

Michael Y. Choi, MD, George F. Widhopf, II, PhD, Jian Yu, PhD, Reilly L Kidwell, BS, BA, CCRC, Laura Z. Rassenti, PhD, Charlene Gutierrez, Susette Gorak, Tiffany Juarez, PhD, Emily Pittman, PhD, Hongying Li, PhD, Karen Messer, PhD, Charles Prussak, PhD, Januario E. Castro, MD, Catriona Jamieson, MD PhD, Thomas J. Kipps, MD, PhD
Journal: Blood
Blood (2016) 128 (22): 3224.
https://doi.org/10.1182/blood.V128.22.3224.3224
Published: 2016